Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 231,079,142 papers from all fields of science
Search
Sign In
Create Free Account
SCH 66712
Known as:
SCH66712
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (2)
Imidazoles
Pyrimidines
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
CYP2D6 Allelic Variants *17-2 & 17-3 Metabolize the Same Substrates as *1 but are Less Susceptibility to Inactivation by SCH 66712
Jacqueline M. Mills
2017
Corpus ID: 92548118
2015
2015
Interactions of Human CYP2D6 Polymorphisms with the Mechanism‐Based Inactivator SCH 66712
Sarah M. Glass
,
V. Osorio
,
Rina Fujiwara
,
M. Glista
,
P. Waal
,
L. Furge
2015
Corpus ID: 82968124
Cytochrome P450 enzymes (CYPs) are a heme‐containing enzyme superfamily that have a major role in the metabolism of drugs in…
Expand
2015
2015
SCH 66712 and EMTPP are the First Potent Mechanism‐Based Inactivators of Both Human CYP2D6 and CYP3A4
Rina Fujiwara
,
Amanda K. Bolles
,
Erran D. Briggs
,
A. Nomeir
,
L. Furge
2015
Corpus ID: 82597300
Cytochrome P450s (CYPs) are heme‐containing enzymes that metabolize small organic molecules including drugs. CYP3A4 and CYP2D6…
Expand
2011
2011
Use of AutoDock Modeling to Understand Inactivation of Human Cytochrome P450 2D6 by SCH 66712
Laura E. Diffenderfer
,
D. Hsi
,
E. Arthur
,
L. Furge
2011
Corpus ID: 82061272
AutoDock is a free‐ware program that simulates ligand‐binding to the active site of a protein based on three‐dimensional…
Expand
1999
1999
High-performance liquid chromatographic analysis of the D4 receptor antagonist SCH 66712 in rat plasma.
H. Kim
,
D. Schuessler
,
C. Bach
,
C. Lin
,
A. Nomeir
Journal of Chromatography B: Biomedical Sciences…
1999
Corpus ID: 20215188
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE